RxDoctor Payments Data

Zoran Grujic, MD

Neurology · Winfield, ILNPI 1033278577

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $19,390 of the $21,584 with a category attached, or 89.8%. Lilly USA, LLC accounts for 77.2% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $8,935, 7.9 times the $1,130 reported in 2020.

$21,584in general payments, 2019–2025

Across 35 payments — averaging $616.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$17K
  • Biogen$5K
  • AbbVie$91
  • Acadia Pharmaceuticals Inc$74
  • Merz Pharmaceuticals, LLC$34
  • Teva Pharmaceuticals USA, Inc.$31
  • plus $57 from 3 others
$42,018in research payments, 2019–2025

Across 5 payments — averaging $8403.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$42K

What the payments were for

  • Consulting fees$1,1305%
  • Speaking & faculty fees$19,39090%
  • Travel & lodging$5543%
  • Food & beverage$5102%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,584 in reported general payments places this provider in the 85th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois →

Medicare billing

Part B allowed, 2024
$253,072
Medicare patients
853
Services billed
2,073

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate12$59,938
Rivastigmine139$23,019
Memantine Hcl744$17,166
Donepezil Hcl597$6,165
AdlarityDonepezil Hcl11$5,857
Carbidopa-LevodopaCarbidopa/Levodopa79$2,638
Memantine Hcl ErMemantine Hcl33$2,271
Divalproex Sodium94$1,519
Bromocriptine Mesylate14$1,388
Methylphenidate Hcl94$1,268
Sertraline Hcl97$1,259
Quetiapine Fumarate62$1,187
Escitalopram Oxalate94$1,183
AmantadineAmantadine Hcl37$1,172
Bupropion Hcl64$1,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$74$59,93812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 790 neurology providers in Illinois.

Other neurology in Winfield

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →